TG Therapeutics Inc Announces UKONIQ (umbralisib) FDA Approval Conference Call Transcript
Greetings, and welcome to the TG Therapeutics FDA Approval Conference Call and Webcast. (Operator Instructions) As a reminder, this conference is being recorded. (Operator Instructions) I would now like to turn the call over to Jenna Bosco, Senior Vice President of Corporate Communications. Please go ahead.
Welcome, everyone, and thank you all for joining us. I'm Jenna Bosco, and with me today to discuss the U.S. Food and Drug Administration's approval of umbralisib, now called UKONIQ, are Michael Weiss, our Executive Chairman and Chief Executive Officer; Dr. Owen O'Connor, our Chief Scientific Officer; and Adam Waldman, our Chief Commercialization Officer.
Mike will begin today's call by providing some introductory comments and context around Friday's FDA approval of UKONIQ for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma. Owen will review the label as well as the clinical data supporting the approval, and Adam will discuss our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |